New insights into treatment of osteoporosis in postmenopausal women

P. Geusens*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


For the prevention of fractures, antiresorptive drugs (bisphosphonates and denosumab) that decrease high bone resorption and, secondarily, also bone formation, are the mainstream of therapy. Osteoanabolic drugs, such as teriparatide, increase bone formation more than bone resorption, and are used in severe osteoporosis, including patients treated with antiresorptive drugs who still lose bone and have recurrent fractures. New potential drugs for fracture prevention that uncouple bone resorption from bone formation include odanacatib, a specific inhibitor of cathepsin-K, the enzyme that degrades bone collagen type I, that inhibits bone resorption and only temporarily bone formation, and monoclonal antibodies against sclerostin (romosozumab, blosozumab), that stimulate bone formation and decrease bone resorption.
Original languageEnglish
Article numbere000051
JournalRMD Open
Issue numberSuppl 1
Early online date15 Aug 2015
Publication statusPublished - 15 Aug 2015

Cite this